Description

Topics in this interactive series focus on critical challenges and complex issues that mental health professionals face today. Our senior faculty include some of the world’s leading clinician-researchers in their respective fields, and they discuss innovative, evidenced-based approaches to managing complex conditions, increasing patient adherence, psychiatric aspects of weight management, implications of DSM-5 diagnostic criteria, novel somatic therapies in psychiatry, and much more.

  • Every session in this series includes live Q&A with faculty – yet each session is also available on-demand, so you can view the entire series or a single session at any time during the year.
  • Use these sessions to educate your entire staff in a community hospital or practice, or simply stay up-to-date as an individual clinician.
  • Earn CME/CE credits for physicians, psychologists, nurses and social workers.


***All broadcasts begin promptly at 11:00 am EDT.***
(Agenda subject to change)

Learning Objectives

At the end of this educational activity, participants should be able to:

  • Review recent changes in DSM-5 and their implications for psychiatric diagnosis and treatment.
  • Identify evidence based psychopharmacological strategies to effectively manage difficult to treat psychiatric disorders.
  • Describe the role of medical device technologies in the treatment of psychiatric illness.
  • Recognize and manage barriers to effective treatment, such as medication side effects and treatment-resistant symptoms.
  • Review novel and best practice treatment approaches to psychiatric disorders in special populations, such as older patients and patients with atypical drug metabolism.

Target Audience

This program is intended for: Psychiatrists, psychologists, primary care/family physicians, nurses, and allied healthcare professionals.

Agenda

***All broadcasts begin promptly at 11:00 am EDT.***
(Agenda subject to change)

 

Current Approaches to Psychosis

 

May 2, 2014

Managing First Episode Psychosis

Abigail Donovan, MD

May 14, 2014

Increasing Patient Adherence through Behavioral and Pharmacologic Strategies

Hannah E. Brown, MD

May 21, 2014

Metabolic Syndrome Update

David C. Henderson, MD

May 28, 2014

Optimal Management of Schizophrenia

Oliver Freudenreich, MD, FAPM

 

Novel Approaches to Depression

 

June 4, 2014

Novel Molecular Targets in the Psychopharmacology of Depression

Maurizio Fava, MD

June 11, 2014

Bipolar Depression Update 2014

Andrew A. Nierenberg, MD 

 

Sleep Disorders

 

June 18, 2014

Sleep Disorders in the Psychiatric Context

John W. Winkelman, MD

 

Psychiatric Aspects of Weight Management

 

June 25, 2014

Mechanisms and Management of Weight Gain with Antipsychotic and Antidepressant Medications

John D. Matthews, MD, MSc

July 2, 2014

Behavioral Approaches to Weight Loss In Psychiatric Patients

(On-Demand)

Louisa Sylvia, PhD

 

DSM-5

 

July 9, 2014

Anxiety, Trauma, and Stress-Related Disorders: A DSM-5 Update

T.H. Eric Bui, MD, PhD

July 16, 2014

DSM-5 Feeding and Eating Disorders

Kamryn T. Eddy, PhD

July 23, 2014

DSM-5: Ready or Not, Here It Is!

Carlene MacMillan, MD

 

Adult ADHD

 

July 30, 2014

Managing Complex Presentations of ADHD in Adulthood

Craig B. Surman, MD

August 6, 2014

Treatment of Pediatric ADHD with Stimulants

Thomas J. Spencer, MD

 

Psychiatry in Special Populations

 

August 13, 2014

New Approaches to the Management of Dementia in Geriatric Patients

Feyza Marouf, MD

August 20, 2014

Pharmacokinetic Differences in Diversity

Albert Yeung, MD

August 27, 2014

Chronic Pain and Psychiatry

David Borsook, MD

 

Novel Somatic Therapies in Psychiatry

 

September 3, 2014

Deep Brain Stimulation for Depression and OCD           

Darin D. Dougherty, MD, MSc

September 10, 2014

Transcranial Magnetic Stimulation

Joan Camprodon-Gimenez, MD, PhD, MPH

September 17, 2014

Brain Stimulation for Neurologic Conditions

Alice W. Flaherty, MD, PhD

Educational Support

This program has received support in the form of educational grants from the following companies: Lilly USA, LLC, Medtronic, Shire Pharmaceuticals

Troubleshooting

If you experience any technical problems with the broadcast, please try the following: 

  1. Test your browser here: www.mghcme.org/systemtest
  2. Review the Participant Guide with FAQ here: http://www.mghcme.org/modernpsychiatryinstructions


Still having difficulty?

Please email us at mghcme@partners.org or call us at (866) 644-7792.

CME Information

Sponsored By:

Partners HealthCare
Partners Vertical
 

Live Event Details

Each one-hour talk is broadcasted live in Boston, MA.

Dates: Broadcasts will occur once a week at 11:00 AM EDT/EST on the following Wednesdays:

  • May 7, 2014
  • May 14, 2014
  • May 21, 2014
  • May 28, 2014
  • June 4, 2014
  • June 11, 2014
  • June 18, 2014
  • June 25, 2014
  • July 2, 2014 (pre-recorded)
  • July 9, 2014
  • July 16, 2014
  • July 23, 2014
  • July 30, 2014
  • August 6, 2014
  • August 13, 2014
  • August 20, 2014
  • August 27, 2014
  • September 3, 2014
  • September 10, 2014
  • September 17, 2014

To receive credit for each of the 20 one-hour sessions, you must view the presentation and complete the post-test and activity evaluation. Upon completion, you will be able to receive one credit for each individual session.

Accreditation 

Partners HealthCare System is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Partners HealthCare System designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


On-Demand Event Details

After the completion of each live activity, the enduring material will be available within 48-72 hours.
Each one-hour talk will be available on-demand for one year.

Release Date: May 7, 2014
Expiration Date: September 17, 2015

Accreditation 

Partners HealthCare System is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Partners HealthCare System designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Psychologists: The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content. This offering meets the criteria for 1 Continuing Education (CE) credit for psychologists.

Social Workers: This program has been approved for 1 Social Work Continuing Education hour for relicensure, in accordance with 258 CMR. Collaborative of NASW and the Boston College and Simmons Schools of Social Work Authorization Number D 61766.

Other Professions: This course allows other providers to claim a Participation Certificate upon successful completion of this course. Participation Certificates will specify the title, location, type of activity, date of activity, and number of AMA PRA Category 1 CreditsTM associated with the activity. Providers should check with their regulatory agencies to determine ways in which AMA PRA Category 1 CreditsTM may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.


Policy on Faculty and Provider Disclosure

In accord with the disclosure policy of Partners HealthCare System as well as guidelines of the Accreditation Council for Continuing Medical Education (ACCME), planners, speakers and/or their spouse/partner or anyone who may have an influence on the content of the activity have been asked to disclose any relationship they or their spouse/partner have to companies producing pharmaceuticals, medical equipment, devices, etc. that may be germane to the content of their presentation. Such disclosure is not intended to suggest or condone bias, but provides participants with information that might be of potential importance to their evaluation of a given presentation.


Resolution of Conflicts of Interest (COI)

Partners HealthCare System has implemented a process to resolve potential COIs for this CME activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public.


Planner Disclosures

The following planners and/or their spouse/partner have reported no relevant financial relationship with a commercial interest.

Tristan Gorrindo, MD
Jane Pimental, MPH

The following planners and/or their spouse/partner have reported a relevant financial relationship with a commercial interest.

Maurizio Fava, MD
Research Support: Abbot Laboratories; Alkermes, Inc.; American Cyanamid; Aspect Medical Systems; AstraZeneca; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon; Clintara, LLC; Covance; Covidien; Eli Lilly and Company;EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; Ganeden Biotech, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; i3 Innovus/Ingenix; Janssen R&D, LLC; Jed Foundation; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; MedAvante;  National Alliance for Research on Schizophrenia & Depression (NARSAD); National Center for Complementary and Alternative Medicine (NCCAM); National Institute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH); Neuralstem, Inc.; Novartis AG; Organon Pharmaceuticals;  PamLab, LLC.; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research Associates., Inc.;  Pharmavite® LLC;PharmoRx Therapeutics;  Photothera; Roche Pharmaceuticals; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC;  Shire; Solvay Pharmaceuticals, Inc.; Synthelabo; Wyeth-Ayerst Laboratories

Advisory/Consulting: Abbott Laboratories; Affectis Pharmaceuticals AG; Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Bayer AG; Best Practice Project Management, Inc.; BioMarin Pharmaceuticals, Inc.; Biovail Corporation; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Cerecor;Clinical Trials Solutions;  CNS Response, Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon Sumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; i3 Innovus/Ingenis; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLCKnoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante, Inc.; Merck & Co., Inc.; MSI Methylation Sciences, Inc.; Naurex, Inc.; Neuralstem, Inc.; Neuronetics, Inc.; NextWave Pharmaceuticals; Novartis AG;Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Otsuka Pharmaceuticals; Pamlab, LLC.; Pfizer Inc.; PharmaStar; Pharmavite® LLC.; PharmoRx Therapeutics; Precision Human Biolaboratory; Prexa Pharmaceuticals, Inc.; Puretech Ventures;  PsychoGenics; Psylin Neurosciences, Inc.; Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Sanofi-Aventis US LLC.; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Synthelabo; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex Pharmaceuticals, Inc.; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda Pharmaceuticals, Inc.

Speaking/Publishing: Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/PrimediaMGH Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource,Corp.; Wyeth-Ayerst Laboratories

Equity Holdings: Compellis; PsyBrain, Inc.

Royalty/patent, other income:

Patent for Sequential Parallel Comparison Design (SPCD), which are licensed by MGH to RCT Logic, LLC; and patent application for a combination of Scopolamine and Ketamine in Major Depressive Disorder (MDD)

Copyright for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory (SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms (DESS), and SAFER; Lippincott, Williams & Wilkins; Wolkers Kluwer; World Scientific Publishing Co. Pte.Ltd.

Michael Hirsch, MD
Honoraria for writing: UpToDate

Jerrold F. Rosenbaum, MD
Equity interest: MedAvante

Equity interest; Board of Directors: PsyBrain

Susan E. Sprich, PhD
Royalties for co-editing book: Oxford University Press, Springer


Educational Support

This program has received support in the form of educational grants from the following companies: Lilly USA LLC, Medtronic, Shire Pharmaceuticals


Hardware/Software Specifications

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration

Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher

Minimum Requirements

Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit


Privacy Policy

Please click here to review our privacy policy.